Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study

• Main Authors: Na Li (Author), Sepehr Shakib (Author), Weilin Qian (Author), Xiaoyan Yao (Author), Puyuan Li (Author), Tsz Keung Nip (Author), Xiaoyan Bai (Author), Kai Shen (Author)
• Format: Book
• Published: Wiley, 2024-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract SHR‐1819 is a novel anti‐IL‐4Rα monoclonal antibody currently under clinical development for use in patients with type 2 inflammatory diseases. In this randomized, double‐blind, placebo‐controlled, single‐dose escalation phase I trial, we evaluated the safety, tolerability, pharmacokinetics...